Zevra therapeutics' miplyffa™ (arimoclomol) receives u.s. fda approval as treatment for niemann-pick disease type c

Miplyffa is the first fda-approved treatment for niemann-pick disease type c (npc), an ultra-rare and progressive neurodegenerative disease

ZVRA Ratings Summary

ZVRA Quant Ranking